Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning provided an update to shareholders regarding the current state of the company. Among other highlights, the update included an overview of Pivot’s plans to generate value for the company and shareholders. “As a business, we see a glaring demand for differentiated products and solutions, backed by proven technologies, that match the vast needs of medicinal and recreational consumers outside of the dried flower segment. We will capitalize on this segment of the market and we are working towards building a sustainable, long-term business with the ultimate goal of delivering value to the consumer and shareholders. Our suite of products remain on track for commercialization in 2018 and beyond. I assure our shareholders that we are working diligently and proactively to create value and restore confidence in Pivot Pharmaceuticals,” Pivot Pharmaceuticals CEO Dr. Patrick Frankham stated in the news release.
To view the full press release, visit http://cnw.fm/y0Ep8
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has licensed or acquired “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based products. Pivot continues to expand its Intellectual Property portfolio. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information, visit the company’s website at www.PivotPharma.com.
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com